Bristol Myers Squibb Teams Up with Jack and Jill of America Inc. to Expand Tomorrow's Innovators Program to Increase Black Representation in the Healthcare Industry

Collaboration to kick off at "The Power of a Dream" National Convention in Orlando, Fla. to bridge professional diversity gaps to emphasize importance of health equity for communities of color

Bristol Myers Squibb NYSE (BMY) announced the first biopharma three-year exclusive collaboration with the premier African American Family Organization, Jack and Jill of America, Inc. to inspire more Black and African American individuals to join the biopharma industry to assist in creating more equity and better health outcomes for all patients through student engagement. The strategic alliance is an extension of BMS' Tomorrow's Innovators Historically Black College (HBCU ) initiative launched with the goal of creating a sustainable bridge of talent to the biopharma industry from the HBCU community and aligns with BMS's inclusion and diversity health equity commitments to increase workforce representation by creating and sustaining a pipeline of diverse talent.

The collaboration will commence at Jack and Jill's bi-annual 45 th National Convention "The Power of a Dream" from July 26-31 in Orlando, Fla., where BMS will be the exclusive biopharma sponsor. The 2022 National Convention will exemplify the power of dreaming and significance of helping children to dream by featuring an interactive legacy gallery of notable Jack and Jill of America alumni in entertainment, business, government, education, media, technology, and social justice, among other industries. BMS will be involved in several events during the convention, including the flagship Programming Luncheon, the Mothers "Closing the Gap: Health, Wealth, and Wellness Forums and Expo" centered around addressing health inequities in the healthcare system and improving healthcare support for communities of color, a virtual career fair and an in-person booth engagement.

"We are so excited to join forces with such a historically prestigious organization like Jack and Jill of America, Inc., to further both of our missions to empower the Black youth to go after their dreams. We hope those dreams include joining the biopharma industry for young Black students," said Shamika Williams, senior director of HBCU initiatives at Bristol Myers Squibb. "In the biopharma industry, there is an immediate need for more diverse representation as it informs the future of medical advancements and resources that directly affect and serve minority communities. We are thrilled to be poised to help bridge this equity gap along with other influential leaders in the space."

"This inaugural collaboration opens the doors for Black and African American youth to learn about opportunities in the biopharma industry," said Kornisha McGill Brown, national president of Jack and Jill of America, Inc. "More representation in the industry helps to drive innovation, which is critical now more than ever to fight inequality in our current health system and to help people and communities achieve better health equity."

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

About Jack and Jill of America, Inc.

Jack and Jill of America, Inc. was founded in 1938 to nurture future African American leaders by stimulating the growth and development of children through educational, cultural, civic, recreational, health and social programs inspired by mothers. Through its 252 chapters organized in seven regions across the United States, Jack and Jill is considered the largest African American family organization in the nation representing 40,000 family members which includes, mother members, fathers, and children ages two through 19. For more information about Jack and Jill of America, Inc. please visit: jackandjillinc.org or @jackandjillinc on Facebook , Instagram , Twitter , Tik Tok , or LinkedIn: Jack and Jill of America, Inc .

philanthropy-news

Bristol Myers Squibb
Media Inquiries:
media@bms.com

News Provided by Business Wire via QuoteMedia

BMY
The Conversation (0)
Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974

Lawsuits have been filed alleging that a number of large corporate employers have offloaded billions of dollars in pension obligations to Athene Annuity and Life Company andor Athene Annuity & Life Assurance Company of New York, subsidiaries of Athene Holding Ltd. (collectively, "Athene") in... Keep Reading...
Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Bristol Myers Squibb Reports First Quarter Financial Results for 2023

Reports First Quarter Revenues of $11.3 Billion Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income Delivers Strong Revenue Growth of 8% from In-Line... Keep Reading...
Bristol Myers Squibb Announces Leadership Transition Plan

Bristol Myers Squibb Announces Leadership Transition Plan

Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed... Keep Reading...
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS®  for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for CAMZYOS® for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

If approved, CAMZYOS would be the first cardiac myosin inhibitor in Europe that specifically targets the source of obstructive HCM Recommendation based on positive Phase 3 EXPLORER-HCM and VALOR-HCM trials demonstrating benefit in patients receiving CAMZYOS versus placebo Bristol Myers Squibb... Keep Reading...
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production

Libertyville, Illinois facility bolsters long-term viral vector supply with multi-product, in-house viral vector production capabilities Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through... Keep Reading...

Latest Press Releases

Related News